Caribou Biosciences (CRBU) EBT (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of EBT data on file, last reported at -$28.1 million in Q1 2026.

• On a quarterly basis, EBT rose 34.68% year-over-year to -$28.1 million in Q1 2026; TTM through Mar 2026 was -$137.2 million, a 36.51% increase from a year earlier, with the FY2025 full-year figure at -$148.7 million, changed 0.29% from the prior year.
• EBT for Q1 2026 stood at -$28.1 million, up from -$28.9 million in the prior quarter.
• Over the last five years, EBT for CRBU reached as high as -$22.7 million in Q1 2022 and fell as low as -$87.4 million in Q1 2024.
• Historically, EBT has averaged -$46.9 million across 5 years, with a median of -$40.3 million in 2024.
• Across the five-year window, EBT sank 431.74% in 2022 and jumped 57.42% in 2025, its largest moves.
• Year by year, EBT stood at -$31.1 million in 2022, then retreated by 20.89% to -$37.6 million in 2023, then decreased by 7.3% to -$40.3 million in 2024, then rose by 28.28% to -$28.9 million in 2025, then advanced by 2.77% to -$28.1 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$28.1 million in Q1 2026, -$28.9 million in Q4 2025, and -$32.4 million in Q3 2025.